Seres Therapeutics Announces Board and Executive Changes
Ticker: MCRB · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Seres Therapeutics reshuffled its board and exec comp. Big changes coming?
AI Summary
Seres Therapeutics, Inc. announced on February 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate underlying strategic shifts or financial pressures that may affect the company's future performance.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- February 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Address of principal executive offices
FAQ
Who has departed from Seres Therapeutics' board or officer positions?
The filing indicates the departure of certain officers and directors, though specific names are not detailed in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 22, 2025.
What is Seres Therapeutics' state of incorporation?
Seres Therapeutics, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 101 Cambridgepark Drive, Cambridge, MA 02140.
What specific items are covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding Seres Therapeutics, Inc. (MCRB).